Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01370811 · ClinicalTrials.gov registry record · Phase 2
A Relative Efficacy and Safety Study of OC Oral Solution for Sialorrhoea in Patients With Parkinson's Disease
A Phase 2 study of Sialorrhoea, sponsored by Orient Pharma Co..
- Completed
- Registry status
- Phase 2
- Development phase
- 24
- Enrollment target
- 1
- Study location
NCT01370811: Completed Phase 2 study of Sialorrhoea, sponsored by Orient Pharma Co..
NCT01370811 is a Phase 2 study of Sialorrhoea that has completed, run by Orient Pharma Co.. The registered enrollment target is 24 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (82% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01370811, a Phase 2 study of Sialorrhoea, has completed, sponsored by Orient Pharma Co..
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 24 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to determine whether OC (oxybutynin and clonidine) oral solution is effective in reducing saliva secretion in patients suffering from Parkinson's Disease with excessive salivation.
Primary Outcome
Change from baseline, negative mean reduce secret rate from baseline, positive mean not reduce secretion.
Conditions Studied
Interventions
- DRUG oxybutynin and clonidine oral solution treatment A
- DRUG oxybutynin and clonidine oral solution treatment B
- DRUG oxybutynin and clonidine oral solution treatment C
- DRUG oxybutynin and clonidine oral solution treatment D
Study Locations (1)
Michigan
- QUEST Research Institute - Bingham Farms
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2011-08 |
| Est. Completion | 2012-09 |
| Phase | Phase 2 |
What the finished NCT01370811 record still lists
NCT01370811 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 24 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (82% lower).
The record links to 1 condition, with Sialorrhoea appearing as the primary indexed condition, and to 4 interventions - of which oxybutynin and clonidine oral solution treatment A is the first listed.
NCT01370811 reports a single indexed study location in Michigan.
Frequently Asked Questions
What is clinical trial NCT01370811 about?
NCT01370811 is a clinical study titled "A Relative Efficacy and Safety Study of OC Oral Solution for Sialorrhoea in Patients With Parkinson's Disease". The purpose of this study is to determine whether OC (oxybutynin and clonidine) oral solution is effective in reducing saliva secretion in patients suffering from Parkinson's Disease with excessive salivation.
What is the current status of trial NCT01370811?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 24 participants. The study started on 2011-08. Estimated completion is 2012-09.
What conditions does trial NCT01370811 study?
This clinical trial studies the following conditions: Sialorrhoea.
What interventions are being tested in trial NCT01370811?
The interventions under investigation include: oxybutynin and clonidine oral solution treatment A (DRUG), oxybutynin and clonidine oral solution treatment B (DRUG), oxybutynin and clonidine oral solution treatment C (DRUG), oxybutynin and clonidine oral solution treatment D (DRUG).
Who is sponsoring clinical trial NCT01370811?
This trial is sponsored by Orient Pharma Co., which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01370811 being conducted?
This trial has 1 study location across Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01370811's enrollment target sits among peer trials
24 1756th of 2000 higher than 217 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02331979 · 24 participants · NA
Improving Bladder Function in SCI by Neuromodulation
- NCT03096197 · 24 participants · NA
Exoskeleton and Spinal Cord Stimulation for SCI
- NCT03223922 · 24 participants · NA
Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases
- NCT03326921 · 24 participants · Phase 1
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia